Skye Bioscience, Inc. SKYE 深 沪
等待开盘 02-07 09:30:00 美东时间
0.826
+0.027
+3.31%
华盛通- 最 高1.15
- 今 开0.8113
- 成交量 3.22万股
- 最 低 0.6844
- 昨 收 0.7995
- 总市值 40.96万
- 52周最高 5.75
- 市盈率 静 --
- 换手率 0.01%
- 52周最低 0.6844
- 委 比 -67.74%
- 总股本 0.00亿
- 历史最高 17.6473
- 量 比 0.27
- 振 幅 58.24%
- 历史最低 0.6844
- 每 手 1
- 风险率 1.10%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Skye Bioscience Presents Nimacimab-Tirzepatide Data At Keystone Obesity Therapeutics Conference
Skye Bioscience, Inc. (NASDAQ:SKYE) ("Skye") a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today presented a poster titled
01-29 20:14
Earnings Scheduled For November 10, 2025
Companies Reporting Before The Bell • CBAK Energy Tech (NASDAQ:CBAT) is likely ...
2025-11-10 19:12
Skye Bioscience to Present Expanded Preclinical CB1 Antibody Data at the American Diabetes Association’s 85th Scientific Sessions
Skye Bioscience to present new nimacimab data at ADA's 85th Scientific Sessions on June 20-23, 2025, in Chicago, highlighting its potential for obesity treatment through a peripherally restricted CB1 inhibitor approach.
2025-06-17 11:00
Skye Bioscience to Participate in Upcoming Investment Conferences
Skye Bioscience will participate in the Jefferies Global Healthcare Conference on June 5 and the Sachs European BioPharma Obesity Innovation Forum on June 11. The company focuses on developing innovative therapies for metabolic health disorders using next-generation molecules. Its Phase 2 trial involves nimacimab, a CB1 inhibitor, either alone or combined with a GLP-1R agonist.
2025-05-22 11:00
Novo Nordisk's Monlunabant Data Drags Stocks Of Smaller Players
Novo Nordisk announced positive Phase 2a trial results for monlunabant, showing significant weight loss with a 10 mg dose. However, investors reacted to limited gains at higher doses. Corbus Pharmaceuticals and Skye Bioscience stocks dropped as all three companies explore CB1 inhibition in obesity treatment.
2024-09-21 03:18
US Stocks Edge Lower; FedEx Earnings Miss Views
U.S. stocks traded slightly lower this morning, with the Dow Jones falling arou...
2024-09-20 21:46
Cantor Fitzgerald Reiterates Overweight on Skye Bioscience, Maintains $14 Price Target
Cantor Fitzgerald analyst Kristen Kluska reiterates Skye Bioscience (NASDAQ:SKYE) with a Overweight and maintains $14 price target.
2024-09-06 22:14
Skye Bioscience Starts Screening Patients for Phase 2 Trial of Potential Weight Loss Drug
07:31 AM EDT, 08/22/2024 (MT Newswires) -- Skye Bioscience (SKYE) said Thursday that it has started screening patients for a phase 2 clinical trial of nimacimab as a weight loss therapeutic for patients with obesity. The company said the trial is targeting enrollment of 120 patients, with weight los...
2024-08-22 19:31
